Skip Navigation



Carcinogenesis Advance Access published online on August 18, 2008

Carcinogenesis, doi:10.1093/carcin/bgn189
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/11/2112    most recent
bgn189v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lin, J.
Right arrow Articles by Wu, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.
Right arrow Articles by Wu, X.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Case-Control Analysis of Nucleotide Excision Repair Pathway and the Risk of Renal Cell Carcinoma

Jie Lin1, Xia Pu1, Wei Wang1, Surena Matin2, Nizar M. Tannir3, Christopher G. Wood2 and Xifeng Wu1

1 Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
2 Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
3 Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Correspondence should be addressed to: Xifeng Wu, M.D., Ph.D., Department of Epidemiology, Unit 1340, The University of Texas M.D. Anderson Cancer Center, 1155 Hermann Pressler Blvd., Houston, Texas 77030. Telephone: (713) 745-2485, Fax: (713) 792-4657, E-mail: xwu{at}mdanderson.org

In this population-based case control study with 325 Caucasian RCC patients and 335 controls matched to cases by age, gender and county of residence, we evaluated the associations between thirteen potential functional polymorphisms in nine major nucleotide excision repair (NER) genes and renal cell carcinoma (RCC) risk. In individual SNP analysis, after adjustment for multiple comparisons, a significantly decreased RCC risk was observed for the heterozygous genotype of XPD Asp312Asn [Odds Ratio (OR) = 0.62; 95% confidence interval (CI) 0.43-0.90] and for the heterozygous and homozygous variant genotypes combined in a dominant model (OR = 0.64; 95% CI 0.46-0.89). The heterozygous AG genotype of XPA 5’UTR was at 1.78-fold increased risk (95% CI 1.18-2.69) and the risk reached 2.43 fold (95% CI 1.57-3.75) for the homozygous variant GG genotype; the risk was significant both in the dominant model and in the recessive model. In joint analysis, compared with individuals with fewer than five adverse alleles, individuals with five (OR = 1.17; 95% CI 0.71-1.93), six (OR = 1.66; 95% CI 1.03-2.67), seven or more (OR = 1.85; 95% CI 1.16-2.95) exhibited a progressively increased risk of RCC (P-for trend = 0.004). Further, there were significant interactions between NER pathway genes and sex, hypertension and obesity (all P-for interaction<0.05). Our results strongly support that common sequence variants of the NER pathway genes predispose susceptible individuals to increased risk of RCC and that the association may be modified by gender, history of hypertension, and obesity. These results need to be replicated in larger studies.

Key Words: Nucleotide excision repair • renal cell carcinoma • case-control study

Received June 9, 2008; revised August 5, 2008; accepted August 5, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.